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Abstract 
 
The successful development of targeted nanotherapeutics is contingent upon the 
conjugation of therapeutic nanoparticles to target-specific ligands, with particular emphasis 
being placed on antibody-based ligands. Thus, new methods that enable the covalent and 
precise installation of targeting antibodies to nanoparticle surfaces are greatly desired, 
especially those which do not rely on costly and time-consuming antibody engineering 
techniques. Herein we present a novel method for the highly controlled and oriented 
covalent conjugation of non-engineered antibody F(ab) fragments to PLGA-PEG 
nanoparticles using disulfide-selective pyridazinedione linkers and strain-promoted alkyne-
azide click chemistry. Exemplification of this method with trastuzumab and cetuximab 
showed significant improvements in both conjugation efficiency and antigen binding 
capability, when compared to commonly employed strategies for antibody-nanoparticle 
construction. This new approach paves the way for the development of antibody-targeted 
nanomedicines with improved paratope availability, reproducibility and uniformity to 
enhance both biological activity and ease of manufacture. 
 
Introduction 
 
The application of nanoparticles as drug delivery vehicles has attracted significant interest 
owing to potential benefits of such platforms, such as improved pharmacokinetic and safety 
profiles of encapsulated cargo. Several nanoformulations are now marketed, whilst 
numerous others are under clinical evaluation.1,2 Many nanoformulations are developed for 
oncology applications in particular.3 Nanoparticles can ‘passively’ accumulate within 
tumours by exploiting defects in neovasculature endothelial junctions and impaired 
lymphatic drainage; a phenomenon known as the enhanced permeability and retention 
(EPR) effect. However, surface functionalisation of nanoparticles with targeting ligands has 
the potential to significantly enhance cellular uptake and retention at the tumour site in a 
concept referred to as ‘active’ targeting.4-6 
 
A variety of ligands have been explored for such purposes, including aptamers, peptides and 
carbohydrates, although antibodies are perhaps the most frequently employed.7-10 
Numerous bioconjugation methods exist to graft these ligands to the surface of 
nanoparticles, with common approaches including carbodiimide and maleimide 
chemistries.11,12 Carbodiimide coupling involves the derivatisation of a carboxyl group with 
cross-linking agents such as 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC), 
followed by their direct conjugation to amines resulting in the generation of an amide bond. 
Depending on the direction of the conjugation, antibodies can be coupled to nanoparticles 
by virtue of free amine or carboxyl functionalities on lysine or aspartic/glutamic acid 
residues, respectively. However, this approach is encumbered by low reaction efficiencies 
and generates highly heterogeneous nanoconjugates, where optimal orientation and 
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functionality of paratopes cannot be guaranteed due to the high abundance of reactive 
amine- and carboxyl-containing residues throughout antibodies. Alternatively, maleimide 
chemistry can in theory facilitate site-specific conjugation to cysteine residues liberated by 
the reduction of the inter-strand disulfide bonds of antibodies.12-14 However, multiple 
reports have questioned the cysteine selectivity of maleimide conjugation under commonly 
employed conditions,15,16 the resultant bioconjugate would bear a thioether bond that has 
been shown to be inherently unstable in vivo,17-19 and such a strategy results in the loss of a 
covalent link between antibody chains. Nonetheless, reports throughout the literature 
demonstrate the advantages of utilising other site-specific chemistries for the generation of 
nanoconjugates, including improved antigen binding and greater product 
homogeneity.9,12,20,21 Many of these approaches involve the installation of site-selective 
amino acid residues using site-directed mutagenesis, followed by subsequent pairing with 
an appropriate reactive group on the nanoparticle surface.9,14,22,23,24,25,26 Whilst this 
approach allows for the oriented presentation of antibody ligands, it is restricted by the 
need for time consuming and expensive antibody engineering.   
 
Given these challenges, novel strategies are required to refine antibody conjugation to 
nanoparticles, with emphasis on: (i) optimising the presentation of the antibody for 
maximal interaction with cognate targets; and (ii) improving the homogeneity and efficiency 
of conjugation of antibodies in their native state to aid manufacturability. Previously, we 
described a novel approach for the functional re-bridging of native inter-strand disulfide 
bonds of full antibodies and their constituent fragments, i.e. resulting in no loss of covalent 
linkage between antibody chains and modifying at positions that are distal from the 
antibody binding site.27-33 This involved the selective insertion of pyridazinedione moieties 
bearing reactive handles into reduced disulfide bonds, thus enabling site-specific 
incorporation of ‘click’ domains without impinging upon antibody functionality. Here we 
describe the application of this disulfide re-bridging technology to site-selectively modify 
trastuzumab (TRAZ) F(ab) to bear a strained alkyne handle distal to the paratope and 
conjugate it to azide-functionalised nanoparticles. This novel approach is compared to 
conventional methods in order to determine the importance of chemical strategy on the 
performance of nanoconjugates (Figure 1). We demonstrate superior binding to HER2 of 
nanoconjugates formed by our new method versus NHS ester conjugation, highlighting the 
potential of this approach to overcome the shortcomings of conventional coupling 
chemistries employed in many targeted nanoformulations to date. 
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Figure 1. Comparison of site-specific conjugation approach versus conventional NHS coupling. Use of a novel 
heterobifunctional linker permits the controlled assembly of a surface corona of F(ab) targeting ligands on 
nanoparticles. The concentrated display of oriented and accessible paratopes afforded by this approach 
maximises target interactions, leading to significantly enhanced avidity versus conventional coupling 
chemistries. 
 
Results and discussion 
 
Our study began with the synthesis of a novel heterobifunctional linker that would facilitate 
conjugation to an antibody disulfide at one end and attachment to a nanoparticle at the 
other. For attachment to the nanoparticle surface, we decided to incorporate the strained 
alkyne BCN due to its ability to engage in copper free strained-promoted alkyl-azide 
cycloaddition (SPAAC) reactions and our confidence in being able to formulate azide-
functionalised nanoparticles (discussed in detail below). Despite wide-spread use within 
biomedical research, SPAAC has remained largely unexplored for the generation of 
nanoconjugates and we took this opportunity to appraise it in this light. To impart site-
selective protein reactivity to the linker, the BCN moiety was linked to a 
dibromopyridazinedione, chosen for its exquisite disulfide reactive selectivity and the 
excellent stability profile of antibody conjugates formed thereof. Synthesis of the strained 
alkyne functionalised pyridazinedione 3 proceeded from readily available starting materials 
in a facile manner over three steps (Scheme 1, further details on the synthetic methods can 
be found in S1-S5 in the ESI).   
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Scheme 1. Synthesis of strained alkyne functionalised pyridazinedione 3. Reagents and conditions: (i) 
Dibromomaleic acid, AcOH, reflux, 24 h; (ii) PyBOP, DIPEA, CH2Cl2, 21 °C, 16 h. 
 
 
 
Figure 2. Modification of TRAZ F(ab) with strained alkyne functionalised pyridazinedione 3. A) Scheme 2: 
Reagents and conditions: (i) 3, TCEP.HCl, BBS pH = 8.0 (2 mM EDTA), 4 °C, 15 h; (ii) Alexafluor®-488-N3 BBS pH 
= 8.0 (2 mM EDTA). B)  LCMS data showing native 4, conjugated 5, and clicked TRAZ F(ab) 6. Spectra have been 
annotated for clarity, see Fig(s) S7, S9 and S12 in the ESI for full spectral data.     
 
The monoclonal antibody TRAZ was chosen as a targeting ligand due to its clinical relevance 
as an approved therapeutic against HER2+ breast cancers.34 The choice to utilise the F(ab) 
domain of TRAZ as the targeting component was driven primarily by the growing volume of 
evidence suggesting antibody fragments provide multiple benefits to the overall 
performance of nanoconjugates when compared to full antibodies; F(ab)s retain the binding 
component of a full antibody.9 Additionally, the use of the F(ab) domain is ideal in that it 
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only contains a single solvent accessible disulfide bond to ensure homogeneous 
modification and that there is only a single site from which the antibody ligand can be 
attached to the nanoparticle. Furthermore, F(ab) domains can be readily expressed and/or 
obtained from native full antibody scaffolds via simple enzymatic digestion procedures. In 
this particular case, we obtained TRAZ F(ab) from native TRAZ via enzymatic digestion 
(pepsin followed by papain, further details provided in the ESI). Site-selective modification 
of TRAZ F(ab) with strained alkyne-pyridazinedione 3 was achieved according to previously 
reported protocols31 (Figure 2A) and confirmed using LCMS (Figure 2B and S9), and SDS-
PAGE showed no aggregation or fragmentation (Figure S8) (hereafter referred to as 
modified TRAZ F(ab) [disulfide] 5). A test click reaction with Alexafluor-488®-azide 
confirmed the presence of the strained alkyne (Figure(s) S10 and S11). As an appropriate 
control to determine the overall effect of the site-directed chemistry, a strained alkyne was 
incorporated into TRAZ F(ab) using non-site-selective lysine-NHS chemistry (modified TRAZ 
F(ab) [lys]) (Figure(s) S13 and S14). Additionally, the F(ab) fragment of cetuximab (CTX) was 
site-selectively modified to provide a control for antigen target specificity (modified CTX 
F(ab) [disulfide]) (Figure(s) S17 and S18). CTX was considered a suitable targeting ligand 
control in this context, given that it does not engage HER2 but rather binds to EGFR, 
another member of the ErbB family of receptor tyrosine kinases.35  
 
Following preparation of the various F(ab) domains, we next explored the potential for site-
specific functionalisation of nanoparticles with modified TRAZ F(ab) [disulfide] 5. To 
facilitate ‘click’ conjugation to this antibody fragment, a novel PLGA nanoparticle 
incorporating a complementary azide moiety was developed. A single emulsion solvent 
evaporation approach was employed to generate a homogeneous population of azide-
terminated nanoparticles from a 25%:75% polymer blend of PLGA-PEG-azide and PLGA 
RG502H (nude azide NP) (Table 1). These nanoparticles were subjected to stability 
assessment over several months, with no significant change in physicochemical 
characteristics observed upon storage at 4 °C or -20 °C (Figure S19). Conjugation of modified 
TRAZ F(ab) [disulfide] 5 to azide-functionalised nanoparticles was then enabled by 
incubating both components for 2 h under ambient conditions, yielding a nanoconjugate 
with a protein loading of 193.1 ± 49.9 pmoles/mg polymer (modified TRAZ F(ab) NP 
[disulfide]) (Table 1). Contrary to our approach, similar reports of the ‘click’ 
functionalisation of nanoparticles via alkyne-azide cycloaddition most often involve copper 
catalysis, which can impart toxicities that ultimately limit the biomedical application of the 
nanoconjugate.36-40 A range of equimolar controls were also formulated in parallel, which 
included: (i) native TRAZ F(ab) 4 conjugated to NHS-functionalised nanoparticles (native 
TRAZ F(ab) NP), (ii) modified TRAZ F(ab) [lys] conjugated to azide-functionalised 
nanoparticles, with the linker chemistry being introduced at lysine residues as opposed to 
reduced disulfides (modified TRAZ F(ab) NP [lys]), (iii) native CTX F(ab) conjugated to NHS-
functionalised nanoparticles (native CTX F(ab) NP) and (iv) modified CTX F(ab) [disulfide] 
conjugated to azide-functionalised nanoparticles (modified CTX F(ab) NP [disulfide]) (Table 
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1). Quantification of F(ab) content within these nanoformulations revealed that conjugation 
via the strained alkyne proceeded with much greater efficiency compared to NHS ester 
chemistry (Table 1). These findings are consistent with the enhanced reaction kinetics of 
SPAAC click chemistry over NHS ester chemistry and also the improved stability of the 
surface bound azide when compared to the activated carboxylic acid. Further 
characterisation experiments included ESEM imaging, which revealed the spherical 
morphology and uniform size distribution of selected nanoformulations, with similar 
diameters to those acquired via dynamic light scattering (DLS) in Table 1 (Figure 3). 
 
Table 1. Characterisation of nanoformulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ESEM imaging of nanoformulations. (A) Modified TRAZ F(ab) NP [disulfide] and (B) native TRAZ F(ab) 
NP were dried on double-sided copper tape mounted onto aluminium stubs, sputter-coated with gold and 
imaged with an ESEM. Scale bar = 4 µm. 
 
Table	1.	Characterisation of	nanoformulations
Nanoformulation Polymer Diameter
(nm)a
PDIa Zeta	potential	
(mV)a
F(ab)	conjugated	
(pmoles/mg	polymer)a,b
Conjugation
efficiency	(%)a
Nude	NHS	NP PLGA-PEG-NHS 191.1	± 1.2 0.16	± 0.01 -4.6	± 0.6 - -
Native	TRAZ	F(ab) NP PLGA-PEG-NHS 210.4	± 2.7 0.18	± 0.01 -3.5	± 0.1 65.3	± 24.0 6.2	± 2.3
Native	CTX	F(ab)	NP PLGA-PEG-NHS 191.2	± 1.8 0.11	± 0.01 -3.9	± 0.4 103.8	± 29.1 9.9	± 2.8
Nude	azide NP PLGA-PEG-azide 187.4	± 1.8 0.02	± 0.01 -2.7	± 0.6 - -
Modified TRAZ	F(ab)	NP	[disulfide] PLGA-PEG-azide 192.4	± 1.5 0.05	± 0.02 -1.9	± 0.7 193.1	± 49.9 18.4	± 4.7
Modified TRAZ	F(ab)	NP	[lys] PLGA-PEG-azide 207.4	± 0.1 0.13	± 0.02 -3.1	± 0.3 475.0	± 221.7 45.2	± 21.1
Modified	CTX	F(ab)	NP	[disulfide] PLGA-PEG-azide 189.9	± 0.2 0.05	± 0.01 -2.3	± 0.1 208.4	± 86.5 19.8	± 8.2
aData	expressed	as	m ean	± SD
b Equ im olar	am ounts	of	each	F(ab )	dom ain	were	in itia lly	added	to	the	nanopartic le	con jugation	reaction
A
B																																																																																																																												
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Having successfully developed modified TRAZ F(ab) NP [disulfide], we next explored the 
ability of the nanoconjugate to bind to the HER2 target receptor. Initial studies employed 
surface plasmon resonance (SPR) to examine binding activity towards a HER2 fusion protein 
immobilised on a carboxymethylated dextran chip. Although binding of native TRAZ F(ab) 
NP was detected via SPR, an equivalent polymer concentration of modified TRAZ F(ab) NP 
[disulfide] showed a significantly enhanced binding profile (Figure 4A). No appreciable 
binding of nude NP (both NHS and azide) or CTX F(ab) NP (both native and modified) 
controls was observed, confirming the dependence of the interaction on TRAZ F(ab). 
Moreover, HER2 binding of modified TRAZ F(ab) NP [lys] was also negligible despite highly 
efficient coupling of the fragment to nanoparticles (see Table 1), indicating that this 
conjugation approach restricted paratope accessibility. This comparison demonstrates that 
the site-selective nature of pyridazinedione conjugation to F(ab) plays a critical role in the 
observed improvements in antigen binding; indicating improved paratope accessibility 
granted by the oriented display of the fragments on the nanoparticle surface.  
 
 
Figure 4. Enhanced binding of modified TRAZ F(ab) NP [disulfide] to HER2 versus native TRAZ F(ab) NP. (A) 
HER2 binding activity of native TRAZ F(ab) NP, modified TRAZ F(ab) NP [disulfide] and associated controls (10 
mg polymer/mL) was assessed by SPR. (B) HER2 binding activity of rhodamine 6G-loaded native TRAZ F(ab) NP, 
modified TRAZ F(ab) NP [disulfide] and associated controls (200 µg polymer/mL) was assessed by modified 
ELISA. Data expressed as mean ± SEM. Statistical significance was established by one-way ANOVA and Tukey’s 
post-hoc test (****p≤0.0001). 
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To exclude the possibility that enhanced binding of modified TRAZ F(ab) NP [disulfide] is a 
consequence of free F(ab) complexation rather than direct coupling to nanoparticles, we 
also analysed HER2 binding capacity by modified ELISA. Rhodamine 6G was encapsulated 
within the various nanoformulations to enable a fluorescent readout of binding to 
immobilised HER2 fusion protein. These studies produced similar trends to earlier SPR 
analyses, demonstrating superior binding to HER2 of modified TRAZ F(ab) NP [disulfide] 
versus native TRAZ F(ab) NP and associated controls (Figure 4B). Consistent with our 
findings, direct comparisons of carbodiimide and click chemistry-based approaches for 
nanoparticle functionalisation have also been described in the literature with a similar 
enhancement in targeting efficiency conferred by the latter.41-45 Several of these reports 
employ full antibodies as targeting ligands whereas our approach offers a distinct advantage 
through the use of F(ab) fragments comprising a sole disulfide bond. This ensures that the 
click-reactive handle is exclusively installed at a single site located distal from the paratope.  
 
The HER2 targeting specificity of modified TRAZ F(ab) NP [disulfide] and native TRAZ F(ab) 
NP was next validated via modified ELISA, where pre-incubation of HER2-coated wells with 
an excess of TRAZ full antibody significantly impeded nanoparticle binding (Figure 5Ai and 
5Aii). These findings were further bolstered by competition modified ELISA formats, where 
simultaneous addition of TRAZ full antibody and modified TRAZ F(ab) NP [disulfide] to HER2-
coated wells inhibited nanoparticle binding in a concentration-dependent manner (Figure 
5B). Collectively, these results demonstrate the successful coupling of TRAZ F(ab) domains 
to NHS- and azide-functionalised nanoparticles by distinct approaches, generating active 
nanoconjugates with retained binding capacity for the cognate HER2 antigen. 
 
Page 9 of 18 Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
ug
us
t 2
01
7.
 D
ow
nl
oa
de
d 
on
 3
0/
08
/2
01
7 
13
:4
8:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C7SC02747H
 Figure 5. HER2 targeting specificity of TRAZ F(ab) NP. (A) HER2 binding activity of (i) native TRAZ F(ab) NP, (ii) 
modified TRAZ F(ab) NP [disulfide] and associated controls (200 µg polymer/mL) was assessed by modified 
ELISA ± pre-block with TRAZ full antibody (20 µg/mL). (B) HER2 binding activity of modified TRAZ F(ab) NP 
[disulfide] (200 µg polymer/mL) was assessed by modified ELISA in competition with TRAZ full antibody 
(0.000051-20 µg/mL). Data expressed as mean ± SEM. Statistical significance was established by one-way 
ANOVA and Tukey’s post-hoc test (****p≤0.0001). 
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We next examined the basis for the enhanced HER2 binding activity of the nanoconjugate 
generated using the site-selective chemistry, modified TRAZ F(ab) NP [disulfide]. To assess 
whether this effect was simply attributed to enhanced F(ab) loading on the nanoconjugate 
rather than optimised paratope orientation, we formulated both native TRAZ F(ab) NP and 
modified TRAZ F(ab) NP [disulfide] using various input amounts of the antibody fragments, 
ranging from approximately 210 to 2100 pmoles per mg polymer. Higher loadings of 
modified TRAZ F(ab) [disulfide] 5 on azide-functionalised nanoparticles were observed, with 
stepwise increases in coupling that correlated with the initial amount of F(ab) added, 
highlighting the unique degree of control afforded by this conjugation approach (Figure 6A). 
As before, enhanced binding of modified TRAZ F(ab) NP [disulfide] was observed upon SPR 
analysis, even when the F(ab) loading was almost half  that of native TRAZ F(ab) NP (Figure 
6A, nanoformulations 5 and 8). This suggests that significant benefits can be achieved even 
in the case of lower F(ab) loadings, establishing the positive effect of using more controlled 
(enabling orientation) chemistries. Intriguingly, this data also revealed that HER2 binding 
activity diminished with higher loadings of modified TRAZ F(ab) [disulfide] 5 on 
nanoparticles, suggestive of potential steric hindrance effects leading to suboptimal 
paratope display. Using fluorescently labelled nanoparticles, these studies were replicated 
via modified ELISA, with comparable findings to SPR analyses (Figure 6B).  
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 Figure 6. Enhanced binding of modified TRAZ F(ab) NP [disulfide] is not attributed to improved protein 
conjugation. (A) HER2 binding activity of native TRAZ F(ab) NP or modified TRAZ F(ab) NP [disulfide] (10 mg 
polymer/mL) with various protein loadings was assessed by SPR. Representative sensorgram shown, with 
corresponding details for numbered samples in the below table. (B) HER2 binding activity of native TRAZ F(ab) 
NP or modified TRAZ F(ab) NP [disulfide] (400 µg polymer/mL) with various protein loadings was assessed by 
modified ELISA. Protein loadings are expressed as pmoles of F(ab) per mg polymer. Data expressed as mean ± 
SEM.  
 
Binding of modified TRAZ F(ab) NP [disulfide] to HER2 was then evaluated in a more 
biologically relevant context using cell-based assays. The nanoconjugate was fluorescently 
labelled via encapsulation of nile red and incubated with the HER2-positive HCC1954 breast 
cancer line (Figure S20), with confocal microscopy demonstrating a clear association of 
modified TRAZ F(ab) NP [disulfide] with these cells (Figure 7A). Co-incubation with an excess 
Page 12 of 18Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
ug
us
t 2
01
7.
 D
ow
nl
oa
de
d 
on
 3
0/
08
/2
01
7 
13
:4
8:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C7SC02747H
of TRAZ full antibody markedly ablated fluorescent labeling of the cells, indicating that the 
binding of the modified TRAZ F(ab) NP [disulfide] was HER2-dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Validation of TRAZ F(ab) functionality in cell-based assays. (A) Confocal microscopy images of 
HCC1954 cells treated with modified TRAZ F(ab) NP [disulfide] encapsulating nile red (400 µg polymer/mL) ± 
TRAZ full antibody (200 µg/mL) for 18 h. Blue and red staining denote nuclei and nanoparticles, respectively. 
Scale bar = 25 µm. (B) BT474 cells were treated with (i) native TRAZ F(ab) NP or (ii) modified TRAZ F(ab) NP 
[disulfide] and associated controls (500 µg polymer/mL). CellTiter-Glo assay was performed at 48, 96 and 144 
h following treatment. Data expressed as mean ± SEM.  
 
In a final series of studies, we examined the therapeutic effects of the TRAZ F(ab) 
nanoconjugates in vitro. These experiments could not be undertaken with the HCC1954 cell 
line used for confocal analyses, given that it shows limited sensitivity to TRAZ. However, 
numerous reports have demonstrated that TRAZ full antibody or its constituent fragments 
can reduce the viability of BT474 breast cancer cells and so this line was deemed an 
appropriate model following confirmation of HER2 expression (Figure S20).46-49 Here, we 
assessed whether TRAZ F(ab) could induce a similar reduction in viability of BT474 cells 
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when presented in a nanoparticle-bound format. Whilst treatment with free native TRAZ 
F(ab) 4 led to a gradual reduction in cell viability over time as anticipated, this effect was 
much less pronounced for the corresponding nanoconjugate (Figure 7Bi). However, upon 
treatment with modified TRAZ F(ab) NP [disulfide], the reduction in cell viability was much 
more comparable to free modified TRAZ F(ab) [disulfide] 5 (Figure 7Bii). These findings are 
consistent with enhanced paratope accessibility on modified TRAZ F(ab) NP [disulfide] 
conferred via the site-specific conjugation approach. Importantly, these studies also 
confirmed that the installation of a pyridazinedione linker did not adversely affect the 
functionality of TRAZ F(ab). Previous work by ourselves and others has shown that antibody 
display on nanoparticle surfaces can enhance receptor cross-linking; thus mimicking ligand 
interactions to enhance downstream biological effects.8,50,51  However, as HER2 is a ligand-
less receptor, it is not surprising that no enhancement of the effect on cell viability was 
observed with these particular non-drug loaded nanoconjugates.  
 
To conclude, we have described a novel strategy for the site-specific functionalisation of 
nanoparticles that promotes the uniform and outward projection of paratopes for maximal 
target interaction. Using TRAZ F(ab) as a model platform, we demonstrate the successful re-
bridging of the inter-chain disulfide bond with a heterobifunctional linker and subsequent 
‘click’ coupling to nanoparticles bearing complementary azide moieties. The controlled 
orientation of TRAZ F(ab) afforded by this approach leads to superior binding to HER2 when 
compared with conventional NHS ester coupling chemistry, with retention of F(ab) 
functionality in cell-based assays, demonstrating the importance of controlled chemical 
ligation for nanoconjugate performance. Crucially, these findings also extend to other 
receptor-ligand pairings including EGFR-cetuximab (Figure S21), highlighting the versatility 
of this novel approach and how it may be tailored for diverse applications. This work offers 
a significant contribution to the ongoing endeavor to refine nanoconjugate design, with the 
aim of generating more controlled, homogeneous systems that can be readily translated. 
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